Company Overview
Torrent Pharmaceuticals is one of India's leading pharmaceutical companies with a strong presence in branded generics, cardiovascular, diabetes, gastroenterology, CNS, and dermatology segments. The company has significant operations across India, Brazil, Germany, and the United States.
Screener Table
| Parameter | Value |
|---|---|
| Current Price | ₹4,469 |
| Market Cap | ₹1.51 Lakh Cr |
| Stock P/E | 67.7 |
| Book Value | ₹250 |
| Dividend Yield | 0.72% |
| ROCE | 27.8% |
| ROE | 26.2% |
| Face Value | ₹5 |
| 52-Week High | ₹4,556 |
| 52-Week Low | ₹3,102 |
| Industry | Pharmaceuticals |
Financial Snapshot
| Metric | FY24 | FY25 |
|---|---|---|
| Revenue | ₹12,700+ Cr | ₹13,900+ Cr (Approx.) |
| Profitability | Strong | Improving |
| ROE | 25%+ | 26%+ |
| ROCE | 26%+ | 27.8% |
| Dividend Yield | 0.7% | 0.72% |
Torrent Pharma continues to generate strong returns on capital while maintaining leadership in chronic therapy segments.
Balance Sheet (Consolidated)
| Particulars (₹ Cr) | FY24 | FY25 | FY26* |
|---|---|---|---|
| Equity Capital | 169 | 169 | 169 |
| Reserves | 6,687 | 7,421 | 8,219 |
| Borrowings | 4,022 | 3,202 | 15,026 |
| Other Liabilities | 3,627 | 3,603 | 20,200 |
| Total Liabilities | 14,505 | 14,396 | 43,614 |
| Fixed Assets | 8,138 | 7,947 | 33,191 |
| Investments | 173 | 156 | 948 |
| Total Assets | 14,505 | 14,396 | 43,614 |
*FY26 reflects the latest reported consolidated balance sheet figures and includes acquisition-related changes.
Key Strengths
✅ Market leader in chronic therapies
✅ Strong brand portfolio in India
✅ ROE above 25%
✅ Consistent cash generation
✅ Presence across 40+ countries
✅ Healthy dividend-paying track record
✅ Strong domestic formulations business
Risks
⚠ High valuation compared with many pharma peers
⚠ Regulatory risks in export markets
⚠ Integration risks from acquisitions
⚠ Increasing competition in generic drugs
⚠ Currency fluctuations impacting overseas revenue
Growth Triggers
| Trigger | Impact |
|---|---|
| India chronic therapy growth | Higher revenue |
| JB Pharma acquisition synergies | Earnings expansion |
| US market launches | Export growth |
| Brazil business expansion | Margin improvement |
| New specialty products | Premium pricing |
Recent market discussions highlight strong earnings growth, expanding domestic business, and strategic acquisitions as major drivers for future growth.
Investment Scorecard
| Factor | Rating |
|---|---|
| Sales Growth | ⭐⭐⭐⭐☆ |
| Profit Growth | ⭐⭐⭐⭐⭐ |
| Balance Sheet | ⭐⭐⭐⭐☆ |
| Return Ratios | ⭐⭐⭐⭐⭐ |
| Valuation | ⭐⭐⭐☆☆ |
| Long-Term Potential | ⭐⭐⭐⭐⭐ |
Verdict
Torrent Pharmaceuticals remains one of the highest-quality pharma companies in India, supported by strong return ratios, dominant branded-generic franchises, and steady earnings growth. While valuation is on the expensive side, long-term investors may continue to track the company for its leadership in chronic therapies, acquisition-led growth strategy, and international expansion.
0 Comments